This article reports what published trial data and clinical observation describe about libido and sexual function on testosterone replacement therapy. It is not medical advice. Sexual symptoms have multiple causes, and a licensed prescriber should evaluate persistent issues.
Of all the symptoms men start TRT to fix, libido is the one with the largest gap between expectation and reality. The marketing implies a switch flips on day one. The trial data shows a curve — fast for some men, slow for others, and incomplete for a meaningful minority. This page maps what published clinical literature and clinic experience describe about that curve: when conscious desire usually returns, when nocturnal erections come back, when erectile function catches up, and what to look at when libido is still flat at month three.
If you are weighing a TRT clinic or trying to decide whether the libido response you are seeing at week 4 is normal, this is the reference page.
What the Trial Data Actually Shows
The largest randomized trial of testosterone replacement specifically powered to evaluate sexual symptoms is the Sexual Function Trial within the broader Testosterone Trials (Snyder et al., 2016). The findings shape what most modern guidelines say about libido on TRT.
Sexual desire improves within the first 3 months
In the Sexual Function Trial, men aged 65 and older with low testosterone and sexual dysfunction received 12 months of testosterone gel. Sexual desire — measured on the Derogatis Inventory of Sexual Function-Male — improved significantly compared to placebo by 3 months and maintained that improvement through 12 months. The early gain was the dominant signal; little additional desire improvement happened after month 3.
Erectile function gains continue out to 12 months
Erectile function, measured on the International Index of Erectile Function, also improved significantly over placebo, but the curve looked different. Gains were smaller in absolute terms, accumulated more gradually, and continued to climb out to 12 months. The data suggest the erectile-function side of sexual response responds to testosterone more slowly than libido does — a pattern multiple other smaller trials echo.
Sexual activity frequency improved modestly
The third sexual-function endpoint — frequency of sexual activity — also rose with testosterone treatment. The effect size was smaller than for desire and erectile function, which is consistent with sexual activity depending on partner availability and relationship factors that no hormone can change.
Not all men responded
Roughly 20-30% of men in the Sexual Function Trial showed minimal or no improvement in sexual symptoms despite achieving mid-normal testosterone levels. This is the most important number on this page. The literature is clear that a meaningful fraction of men with low testosterone and low libido do not get the libido they wanted from TRT alone, even when labs are corrected.
Week-by-Week Libido Curve on TRT
The timeline below synthesizes the trial data above with patterns observed in clinic populations and described in real-world cohort studies. Use it as orientation, not a guarantee.
| Time on TRT | What Most Men Report | What the Data Supports |
|---|---|---|
| Week 1-2 | Mood lift, slight energy increase, mixed libido changes | Testosterone levels rising toward target range; sexual response pathways still adapting |
| Week 2-4 | Morning erections reappear; spontaneous arousal returns | Earliest measurable change in nocturnal penile tumescence in trial data |
| Week 4-6 | Conscious sexual desire begins to climb noticeably | First detectable separation from placebo on desire scores in most trials |
| Week 6-12 | Libido settles into a new baseline; "honeymoon" peak fades | Sexual desire scores plateau; consistent with Snyder et al. 3-month curve |
| Month 3-6 | Erectile function continues to improve; libido stable | Erectile function gains accumulate beyond the libido plateau |
| Month 6-12 | Mature sexual response established | Endpoint of the Sexual Function Trial; no further large gains expected |
What "morning wood" actually tells you
Spontaneous nocturnal and morning erections are governed largely by testosterone-driven central pathways. Their reappearance early in TRT is a useful early signal that the testosterone signal is working at the level of the brain. If morning erections come back within 2-4 weeks but daytime libido stays low, the hormonal piece is doing its job and the missing piece is psychological, relational, or pharmacological — not a testosterone deficiency.
What the "honeymoon" peak is and is not
Many men describe a libido surge in the first 2-6 weeks that fades. This is consistent with the rapid rise from a low baseline to a corrected level, similar to the contrast effect of any stimulus that suddenly becomes available after a long absence. The fade is not a treatment failure — the settled libido is the meaningful endpoint, and it is usually higher than the pre-TRT baseline even after the honeymoon is over.
When Libido Is Still Flat at Month 3
If trough total testosterone is in target range, free testosterone is in target range, and libido is still flat at the 3-month mark, the literature points to a short list of usual suspects.
Estradiol off range — high or low
Estradiol matters for male libido in both directions. Trial and observational data describe libido suppression both above the upper end of the male reference range and below it. Men whose estradiol management on TRT has driven E2 down to single-digit pg/mL through aggressive aromatase inhibition often report worse libido than at baseline. Men running E2 in the 60-80 pg/mL zone with high aromatization can also report dampened response. The middle-of-range zone — roughly 25-45 pg/mL on standard immunoassay or 20-40 pg/mL on LC/MS — is where most men land for best sexual response.
Prolactin elevation
Hyperprolactinemia suppresses libido and is sometimes missed at baseline. Routine prolactin checks at 3 months are part of careful workups and can identify a pituitary cause that testosterone alone will not fix.
SSRIs and 5-alpha reductase inhibitors
Two medication classes are the most common pharmacologic libido killers in the TRT population:
- SSRIs and SNRIs suppress libido and delay or block orgasm in a substantial fraction of users. Switching to a less libido-suppressive antidepressant (bupropion, mirtazapine) sometimes restores response when testosterone alone has not.
- Finasteride and dutasteride suppress DHT, which mediates a meaningful share of male sexual response. Persistent low libido despite in-range testosterone in a man on a 5-alpha reductase inhibitor is a recognized phenomenon — sometimes called post-finasteride syndrome in the more durable cases.
Sleep apnea and chronic sleep restriction
Untreated sleep apnea suppresses both testosterone and the central drive that testosterone enables. A clinic that treats TRT seriously will screen for sleep apnea before and during therapy, because polycythemia and persistent symptoms both intersect with sleep.
Relationship, stress, and mental-health load
Libido does not exist in a vacuum. Trial data and clinic experience both describe persistent low libido in men with normalized testosterone whose primary driver is relational distance, chronic stress, or untreated depression. Testosterone is necessary but not sufficient for sexual desire; the rest of the picture has to support it.
Erectile Function vs Libido — Two Different Curves
A common source of confusion: libido and erectile function are different mechanisms with different response patterns to testosterone.
Libido is mostly central
Sexual desire is driven by central nervous system pathways — particularly the hypothalamus and limbic system — where androgen receptors are dense. Restoring testosterone restores the central drive. This is why libido responds quickly and largely settles by month 3 for responders.
Erectile function has central and peripheral components
The erection itself depends on intact vascular, neurogenic, and tissue-level mechanisms. Testosterone supports these systems but cannot create them. A man with vascular erectile dysfunction from years of metabolic syndrome may see his desire return on TRT but find that mechanical erections still need a PDE5 inhibitor or other support. Trial data show erectile function gains from testosterone alone, but the effect size is smaller than for libido and the gains accumulate over a longer period.
What to do when libido returns but erections lag
The clinical pattern that most experienced TRT prescribers describe: at month 3, conscious desire and morning erections are both present, but daytime erections during sex feel less reliable than expected. The standard workup at that point is a vascular evaluation (lipids, blood pressure, fasting glucose), a check on PDE5 responsiveness, and consideration of whether the man is overreaching at a dose that is correct for libido but suboptimal for vascular response.
Injection Frequency, Trough Levels, and Libido Stability
The timing of testosterone delivery influences the libido curve from week to week, not just over months.
Once-weekly intramuscular: peaks and troughs
A once-weekly intramuscular cypionate or enanthate protocol produces serum levels that climb sharply post-injection, peak around days 2-4, and decline through day 7. Many men report better libido in the first half of the cycle and a noticeable drop in the second half. This is not a treatment failure — it is the predictable shape of a once-weekly ester.
Twice-weekly or every-other-day: smoother
Splitting the same weekly dose into smaller injections two or three times a week, or every other day with subcutaneous injection, smooths the trough-to-peak swing. Men who are sensitive to the libido swing in once-weekly protocols often report more consistent sexual response on a more frequent schedule. The total weekly dose does not change; only the curve does. See injection frequency: weekly vs every-other-day for the full comparison.
Why this matters for the timeline
If you are tracking your libido response week to week, knowing where you are in the injection cycle matters. A "bad libido week" four days after a weekly injection probably reflects the trough end of the curve, not a treatment failure. The signal worth tracking is the average response over multiple weeks, not a single low point.
What This Looks Like in a Clinic That Manages It Well
A clinic that takes sexual response seriously builds the libido timeline into the workup rather than promising a fast fix. The pattern most experienced TRT clinics follow:
- Baseline workup includes total testosterone, free testosterone, SHBG, estradiol, prolactin, TSH, and a libido/sexual-function questionnaire.
- Patient is told to expect a 3-month curve, with morning erections often returning earlier than conscious desire.
- Recheck labs at 6-8 weeks. If trough total and free testosterone are in target and libido has not started to move, the clinic re-evaluates estradiol, prolactin, sleep, and medications rather than reflexively raising the testosterone dose.
- If labs are correct at 3 months and libido is still flat, the clinic investigates non-testosterone drivers and considers PDE5 inhibitors, SSRI swap, sleep evaluation, or referral to a urologist or sexual-medicine specialist.
- Dose changes are made for symptoms or trough levels — not for impatience with the timeline.
If a clinic is willing to raise your dose at week 4 because libido has not surged yet, that is a flag. The trial data does not support a meaningful libido response to dose escalation in the first month, and pushing trough levels above target rarely helps libido and frequently worsens estradiol, hematocrit, and sleep. The clinic comparison hub ranks clinics by how disciplined they are about this exact pattern.
Common Pitfalls in Reading the Libido Timeline
Forum posts and DIY protocols frequently misread the libido response in ways that lead to bad dose decisions. The most common errors:
- Calling week 2 a treatment failure. Sexual desire scores in the trial literature did not separate from placebo until weeks 4-6 in most studies. Week 2 is too early to evaluate.
- Assuming the honeymoon peak is the new baseline. The 2-6 week libido surge fades for almost everyone. The settled level at month 3 is the meaningful endpoint.
- Pushing the dose to chase libido. Above mid-normal testosterone, libido is more often suppressed by elevated estradiol, prolactin, or sleep disruption than helped by additional testosterone.
- Ignoring estradiol when libido is flat. A man with in-range testosterone and out-of-range estradiol — high or low — often has a libido problem driven by E2, not T.
- Conflating libido with erectile function. Strong desire with unreliable erections is a different problem than low desire with reliable erections. The workups are different and the treatments are different.
Bottom Line
Libido on TRT follows a curve, not a switch. Trial data shows most men get the majority of the libido improvement they will get within the first 3 months, with morning erections often returning earlier than conscious desire and erectile function continuing to improve out to 6-12 months. About 20-30% of men do not get a meaningful libido response from testosterone alone, and the literature points to estradiol, prolactin, medications, sleep, and relationship factors as the usual culprits. The right move at week 4 is patience and lab review, not a dose increase. The right move at month 3 with flat libido is a workup, not a higher dose. A clinic that respects the curve and the workup is the one most likely to deliver the response you started TRT for.